Surinabant (SR 147778) is an orally active, selective cannabinoid receptor type 1 CB1R antagonist. Surinabant is used in studies of obesity and alcoholism [1] [2].
References:
[1]. Klumpers LE, et al. Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans. Br J Clin Pharmacol. 2013 Jul;76(1):65-77.
[2]. Fischler PV, et al. Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. Front Pharmacol. 2022 Oct 3;13:927703.
References:
[1]. Klumpers LE, et al. Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans. Br J Clin Pharmacol. 2013 Jul;76(1):65-77.
[2]. Fischler PV, et al. Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. Front Pharmacol. 2022 Oct 3;13:927703.
















